StockIQ.techGuardant Health, Inc. (GH) Stock Analysis
Free AI-powered analysis and research for Guardant Health, Inc. stock
Sector: Healthcare
GH snapshot
Data as of 3 Nov 2026 close. Updated daily.
Guardant Health, Inc. scores 88/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 86% of its 52-week range, up 76.5% over the past year. Latest reported figures show a profit margin of -38.3% and revenue growth of +44.3%.
What is driving the score
- RSI Neutral: +5
- Uptrend: +4
- MACD Bullish: +8
- Strong Revenue Growth (44.3%): +8
- Unprofitable (-38.3%): -15
- Strong Liquidity (4.03 Current Ratio): +8
- Low P/B (-107.19): +5
- Strong Long-term Uptrend: +8
- Strong Rise (+76.5% over 1 year): +10
- Low Volume (0.4x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full GH report
Guardant Health, Inc. (GH) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze GH Now →📰 Latest Update
Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Thu, October 29, 2026 at 1:00 PM UTC 4 min read
Guardant Health (GH) is anticipated to exceed earnings estimates in its upcoming Q3 release, driven by strong demand for its cancer detection and monitoring solutions. This positive outlook is significant for investors as it may indicate robust operational performance and potential growth, which could enhance shareholder value. Investors should closely monitor the earnings report for insights into the company's financial health and future prospects.